Immunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ Lab

SEATTLE, May 11, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the upcoming American Thoracic Society International Conference on May 18 in San Francisco.

Presentation Title: "Validation of a Novel Host Response Assay to Distinguish SIRS and Sepsis in Critically Ill Patients"

Poster Discussion Session: D104 - Critical Care: Pre-ICU, Rapid Response, And Initial Treatment For Sepsis
Presenter: Dr. Russell R. Miller, III
Date: Wednesday, May 18, 2016
Time: 1:30 PM-3:30 PM PDT
Location: Room 3024 (West Building, Level 3), Moscone Center

Additional information may be found at http://conference.thoracic.org/

Sepsis is a life-threatening condition that arises when the body's response to infection damages its own tissues and organs. Diagnosis of sepsis today relies on medical impression based on a combination of clinical parameters and later pathogen detection and therefore has serious limitations in respect of speed and sensitivity. The Immunexpress SeptiCyte™ LAB solution evaluates the patient's own immune response to infection to aid clinicians in quickly and accurately diagnosing sepsis in patients suspected of sepsis.

About Immunexpress

Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with sepsis and suspected of sepsis. Immunexpress's SeptiCyte™ technology quantifies directly from whole blood specific molecular markers from the patient's own immune system. Detecting the patient's septic immune response has the potential to identify sepsis earlier, faster and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen; the immune response is independent of whether or not the pathogen is in the blood sample. Immunexpress's pipeline includes assays for readily available lab-based platforms, as well as point-of-care (POC) sample-to-answer instrumentation. For more information visit www.Immunexpress.com.

Follow Immunexpress on Twitter at twitter.com/Immunexpress and LinkedIn at www.linkedin.com/company/immunexpress-inc.

Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners 
(212) 845-4271
(212) 845-4262  
[email protected] 
[email protected]

SOURCE Immunexpress, Inc.

Related Links

http://www.Immunexpress.com